Structure Therapeutics (GPCR) Equity Average (2022 - 2026)

Structure Therapeutics' Equity Average history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Equity Average rose 75.41% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 75.41% YoY), while the FY2025 annual figure was $1.2 billion, up 80.7% from the prior year.
• Equity Average was $1.5 billion for Q1 2026 at Structure Therapeutics, up from $1.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.5 billion in Q1 2026 to a low of -$109.5 million in Q4 2022.
• Historically, Equity Average has averaged $529.1 million across 5 years, with a median of $558.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Equity Average jumped 628.3% in 2024, then fell 15.17% in 2025.
• A 5-year view of Equity Average shows it stood at -$109.5 million in 2022, then jumped by 394.87% to $323.0 million in 2023, then soared by 172.73% to $880.8 million in 2024, then climbed by 29.79% to $1.1 billion in 2025, then rose by 29.61% to $1.5 billion in 2026.
• The last three Equity Average figures came in at $1.5 billion (Q1 2026), $1.1 billion (Q4 2025), and $771.0 million (Q3 2025), per Business Quant data.